Last $0.31 USD
Change Today -0.0464 / -13.13%
Volume 3.0M
HEB On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 8:04 PM 04/15/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Robert Dickey IV

Chief Financial Officer and Vice President, Neostem, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 5 different industries.

57$435,371
As of Fiscal Year 2013

Background*

Mr. Robert Dickey, IV, also known as Rob, serves as Chief Financial Officer of Neostem, Inc. Mr. Dickey serves as Managing Director of DSS Partners LLC. Mr. Dickey served as a Senior Vice President of Hemispherx Biopharma, Inc. since June 2009 until August 16, 2013. Mr. Dickey served as the Chief Financial Officer and Senior Vice President of StemCyte, Inc. since July 2007. He served as the Chief Financial Officer and Vice President of Finance of Locus Pharmaceuticals, ...

Read Full Background

Corporate Headquarters*

One Penn Center
Philadelphia, Pennsylvania 19103

United States

Phone: 215-988-0080
Fax: 215-988-1739

Board Members Memberships*

Former Senior Director

Education*

Bachelor's Degree
Princeton University
BA
Princeton University
MBA
University of Pennsylvania - The Wharton School

Other Affiliations*

Annual Compensation*

Salary$150,626
Bonus$40,000
Total Annual Compensation$190,626

Stock Options*

All Other Compensation$15,283

Total Compensation*

Total Annual Cash Compensation$205,909
Total Short Term Compensation$190,626
Other Long Term Compensation$15,283
Total Calculated Compensation$435,371
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HEB:US $0.31 USD -0.0464

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Gil Van Bokkelen Ph.D.Co-Founder, Chairman and Chief Executive Officer
Athersys, Inc.
$568.8K
Michael D. West Ph.D.Chief Executive Officer, President and Director
BioTime, Inc.
$760.5K
Marc H. Hedrick M.D.Chief Executive Officer, President and Director
Cytori Therapeutics, Inc.
$406.6K
Martin P. Rosendale Chief Executive Officer and Director
Cytomedix, Inc.
$467.3K
Zami Aberman Executive Chairman and Chief Executive Officer
Pluristem Therapeutics, Inc.
$544.2K
Compensation as of Fiscal Year 2013.

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEMISPHERX BIOPHARMA INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.